Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain

Toth, Cory

doi:10.1177/2042098613505614

Cited by 152 publications

(142 citation statements)

References 126 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The binding at pre-and post-synaptic membranes results in inhibition of the release of excitatory neurotransmitters [9]. This a2d1 subunit-binding is considered to account for both antinociceptive and probably antiseizure effects as well [10]. Additionally, this mechanism correlates with a growing number of clinical trials indicating that gabapentin and pregabalin could be effective as postoperative analgesics [11].…”

Section: Introductionmentioning

confidence: 99%

Preclinic and clinic effectiveness of gabapentin and pregabalin for treatment of neuropathic pain in rats and diabetic patients

Surcheva

Todorova

Maslarov

et al. 2017

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Pregabalin and gabapentin are amino-acid derivatives of gamma-aminobutyric acid. They have a high affinity to the a2d protein in the central nervous system and both have been shown to be effective for neuropathic pain disorder. The aim of this study was to investigate the efficacy of gabapentin and pregabalin in animal models of neuropathic pain, and to correlate with clinical outcomes in patients with diabetic neuropathy. Gabapentin (60 mg/kg) and pregabalin (30 mg/kg) attenuate mechanical, tactile and heat hypersensitivity in rats with chronic constriction injury of the sciatic nerve and streptozotocin (STZ)-induced diabetes. There is no evidence that one of the drugs is superior to another at the different rat models and tests. In the incisional pain model, there was partial efficacy of gabapentin. Our clinical data suggest that relative to the baseline pain score, the treatment with pregabalin at doses of 300 mg/day or gabapentin at doses of 900 mg/day would be effective and well tolerated in patients diagnosed with moderate diabetic polyneuropathy. The study suggested that pregabalin may provide better analgesic outcomes than gabapentin on the sixth month of treatment. In conclusion, the comparative effects of gabapentinoids in animal models of neuropathic pain and neuropathic patients are suggestive of similar pathophysiological mechanisms being involved, but successful outcome is determined by a patient's individuality and the drug nature as well as the drug tolerability.

show abstract

Section: Introductionmentioning

confidence: 99%

Preclinic and clinic effectiveness of gabapentin and pregabalin for treatment of neuropathic pain in rats and diabetic patients

Surcheva

Todorova

Maslarov

et al. 2017

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…The study of the adverse effects of pregabalin as an analgesic has also been done. The side effects include somnolence, dizziness, peripheral oedema, and dry mouth [21]. The FDA has licensed the use of pregabalin for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN), post-herpetic neuralgia (PHN), and adjunctive therapy in an adult partial seizure.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Study: The Off-Label Use of Anticonvulsants at a Private Hospital in Indonesia

Rahajeng

Ikawati

Andayani

et al. 2018

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Anticonvulsant is one class of drugs often used off-label. This study was conducted to investigate the prevalence and the indication of the off-label use of anticonvulsants in a private hospital in Java, Indonesia. Methods:This was an observational study with a retrospective data collection in a private hospital in Java. Data were obtained on the prescription of anticonvulsants. Indications of the use of anticonvulsants were obtained from the medical records of patients who were prescribed anticonvulsants. The off-label use of anticonvulsants was defined a prescribing of medication outside the indication approved by The National Agency of Drug and Food Control Indonesia (NA-DFC). The use off-label of anticonvulsants was calculated by descriptive analysis and presented as a percentage.Results: It showed that in one year there were 5,310 for 1,316 patients: of this 462 patients (35.11%) were for an off-label use. The anticonvulsants used off-label were oxcarbazepine 67.27% (37/55), carbamazepine 46.15% (54/117), pregabalin45.45% (60/132), phenytoin37.62% (225/598), valproate 25.34% (37/109), and gabapentin 18.28% (49/219). The highest off-label use of anticonvulsants was found in neurological and psychiatric disorders 67.32% (n=311), and on 97.19% of them were not supported by strong clinical evidence. Conclusion:The off-label use of anticonvulsants occurred in one-third of patients receiving prescriptions of anticonvulsants, even though for most of them there was a lack of evidence. More attention must be paid to the efficacy and risk of side effects of the drug used.

show abstract

“…These side effects are dose-dependent. 19,20 This study had no control group; hence, it cannot study the placebo effect on the parameters. The 75 mg/day dose of pregabalin was considered safe for Indonesians, while the recommended dosage from previous studies was 125-600 mg/day.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain

Rahajeng¹,

Ikawati²,

Andayani³

et al. 2018

JYP

View full text Add to dashboard Cite

Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain

Cited by 152 publications

References 126 publications

Preclinic and clinic effectiveness of gabapentin and pregabalin for treatment of neuropathic pain in rats and diabetic patients

Preclinic and clinic effectiveness of gabapentin and pregabalin for treatment of neuropathic pain in rats and diabetic patients

A Retrospective Study: The Off-Label Use of Anticonvulsants at a Private Hospital in Indonesia

The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain

Contact Info

Product

Resources

About